HIV-1 env glycoproteins from two series of primary isolates: Replication phenotype and immunogenicity

Virology

Volumn 229, Issue 1, 1997, Pages 269-278

  Mustafa, Farah ^a,d   Richmond, Joan F L ^a   Fernandez Larsson, Roberto ^b   Lu, Shan ^e   Fredriksson, Robert ^c   Fenyö, Eva Maria ^c   O'Connell, Maryellen ^a   Johnson, Eric ^e   Weng, Jayu ^a   Santoro, Joseph C ^a   Robinson, Harriet L ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CHILDREN S RESEARCH INSTITUTE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL; RABBIT; VIRUS ENVELOPE; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 0031550774     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8445     Document Type: Article

References (42)

1. Adachi, A., Gendelman, H. E., Koenig, S., Folks, T., Willey, R., Rabson, A., and Martin, M. A. (1986). Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J. Virol. 59, 284-291.
2. Åsjö, B., Albert, J., Karlsson, A., Morfeldt-Manson, L., Biberfeld, G., Lidman, K., and Fenyö, E. M. (1986). Replicative properties of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 2, 660-662.
3. Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso, P., and Norcross, M. A. (1994). Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68, 6006-6013.
4. Chapman, B. S., Thayer, R. M., Vincent, K. A., and Haigwood, N. L. (1991). Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res. 19, 3979-3986.
5. Cheng-Mayer, C., Seto, D., Tateno, M., and Levy, J. A. (1988). Biologic features of HIV-1 that correlate with virulence in the host. Science 240, 80-82.
6. Delwart, E. L., Sheppard, H. W., Walker, B. D., Goudsmit, J., and Mullins, J. I. (1994a). Human immunodeficiency virus type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J. Virol. 68, 6672-6683.
7. Delwart, E. I., Shpaer, E. G., Louwagie, J., McCutchan, F. E., Grez, M., Rubsamen-Waigmann, H., and Mullins, J. I. (1994b). Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 262, 1257-1261.
8. Earl, P. L., Broder, C. C., Long, D., Lee, S. A., Peterson, J., Chakrabarti, S., Doms, R. W., and Moss, B. (1994). Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody activities. J. Virol. 68, 3015-3026.
9. Eisenbraun, M. D., Fuller, D. H., and Haynes, J. R. (1993). Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. DNA Cell Biol. 12, 791-797.
10. Fenyö, E. M., Albert, J., and Åsjö, B. (1989). Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 1989 3(suppl. 1), S5-S12.
11. Fenyö, E. M., Albert, J., and McKeating, J. (1996). The role of the humoral immune response in HIV infection. AIDS 1996 10(suppl. A), S97-S106.
12. Fenyö, E. M., Morfeldt-Manson, L., Chiodi, F., Lind, B., von Gegerfelt, A., Albert, J., Olausson, E., and Asjo, B. J. (1988). Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J. Virol. 62, 4414-4419.
13. Fernandez-Larsson, R., Srivastava, K. K., Lu, S., and Robinson, H. L. (1992). Replication of patient isolates of human immunodeficiency virus type 1 in T cells: A spectrum of rates and efficiencies of entry. Proc. Natl. Acad. Sci. USA 89, 2223-2226.
14. Fuller, D. H., and Haynes, J. R. (1994). A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res. Hum. Retroviruses 10, 1433-1441.
15. Gibbs, J. S., Regier, D. A., and Desrosiers, R. C. (1994). Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retroviruses 10, 333-342.
16. Helseth, E., Kowalski, M., Gabuzda, D., Olshevsky, U., Haseltine, W., and Sodroski, J. (1990). Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J. Virol. 64, 2416-2420.
17. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., and Markowitz, M. (1995). Rapid turnover of plasmid virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 373, 123-126.
18. Kabat, D., Kozak, S. L., Wehrly, K., and Chesebro, B. (1994). Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1. J. Virol. 68, 2570-2577.
19. Kent, K. A., and Robinson, J. (1996). Antigenic determinants on HIV-1 envelope glycoproteins: a dickens of a time with oligomer twist. AIDS 1996 10(suppl. A), S107-S114.
20. Koot, M., Vos, A. H. V., Keet, R. P. M., de Goede, R. E. Y., Dercksen, M. W.,Terpstra, F. G., Coutinho, R. A., Miedema, F., and Tersmette, M. (1992). HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992 6, 49-54.
21. Leonard, C. K., Spellman, M. W., Riddle, L., Harris, R. J., Thomas, J. N., and Gregory, T. J. (1990). Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265, 10373-10382.
22. Lu, S., Santoro, J. C., Fuller, D. H., Haynes, J. R., and Robinson, H. L. (1995). Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 209, 147-154.
23. Lu, S., Arthos, J., Montefiori, D. C., Yasutomi, Y. Manson, K., Mustafa, F., Johnson, E., Santoro, J. C., Wissink, J., Mullins, J. I., Haynes, J. R., Letvin, N. L., Wyand, M., and Robinson, H. L. (1996). Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70, 3978-3991.
24. Moore, J. P., and Ho, D. D. (1995). HIV-1 neutralization: The consequences of viral adaptation to growth on transformed t cells. AIDS 9(suppl. A), S117-S136.
25. Moore, J. P., and Sodroski, J. (1996). Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70, 1863-1872.
26. Moore, J. P., Cao, Y., Leu, J., Qin, L., Korber, B., and Ho, D. D. (1996). Inter- and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70, 427-444.
27. Myers, G., Wain-Hobson, S., Henderson, L. E., Korber, B., Jeang, K.-T., and Pavlakis, G. N. (1994). "Human Retroviruses and AIDS 1994," Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
28. Okuda, K., Bukawa, H., Hamajima, K., Kawamoto, S., Sekigawa, K.-I., Yamada, Y., Tanaka, S.-I., Ishii, N., Aoki, I., Nakamura, M., Yamamoto, H., Cullen, B. R., and Fukushima, H. (1995). Induction of potent humoral and cell-mediated immune responses following direct injection of DNA encoding the HIV type 1 env and rev gene products. Aids Res. Hum. Retroviruses 11, 933-943.
29. Pertmer, T. M., Eisenbraun, M. D., McCabe, D., Prayaga, S. K., Fuller, D. H., and Haynes, J. R. (1995). Gene gun-based nucleic acid immunization: Elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13, 1427-1430.
30. Reiter, J. N., Sergel, T., and Morrison, T. G. (1995). Mutational analysis of the leucine zipper motif in the Newcastle disease virus fusion protein. J. Virol. 69, 5995-6004.
31. Richmond, J. F. L., Mustafa, F., Lu, S., Santoro, J. C., Weng, J., O'Connell, M., Fenyo, E. M., Hurwitz, J. L., Montefiori, D. C., and Robinson, H. L., submitted.
32. Robinson, J. E., Holton, D., Lui, J., McMurdo, H., Murciano, A., and Gohd, R. (1990). A novel enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to HIV-1 envelope glycoproteins based on immobilization of viral glycoproteins in microtiter wells coated with concanavalin A. J. Immun. Methods 132, 63-71.
33. Robinson, H. L., Feltquate, D. M., and Morin, M. L. (1995). DNA vaccines: A new approach to immunization. In "Vaccines 95" (F. Brown, R. Chanock, and H. Ginsberg, Eds.), pp. 65-70. Cold Spring Harbor Press, Cold Spring Harbor, NY.
34. Stamatos, L., and Cheng-Mayer, C. (1995). Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and different V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J. Virol. 69, 6191-6198.
35. Sullivan, N., Sun. Y., Li, J., Hoffmann, W., and Sodroski, J. (1995). Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69, 4413-4422.
36. Tersmette, M., de Goede, R. E. Y., Al, G. J. M., Winkel, I. N., Gruters, R. A., Cuypers, H. T., Huisman, H. G., and Miedema, F. (1988). Differential syncytium-inducing capacity of human immunodeficiency virus isolates: Frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrom (AIDS) and AIDS-related complex. J. Virol. 62, 2026-2032.
37. Tersmette, M., Gruters, R. A., de Wolf, F., de Goede, R. E. Y., Lange, J. M. A., Schellenkens, P. T. A., Goudsmit, J., Huisman, H. G., and Miedeman, F. (1989). Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: Studies on sequential HIV isolates. J. Virol. 63, 2118-2125.
38. von Gegerfelt, A., Albert, J., Morfeldt-Manson, L., Broliden, K., and Fenyö, E. M. (1991). Isolate-specific neutralizing antibodies in patients with progressive HIV-1 related disease. Virology 185, 162-168.
39. Wang, B., Ugen, K. E., Srikantan, V., Agadjanyan, M. G., Dang, K., Refaeli, Y., Sata, A. I., Boyer, J. Williams, W. V., and Weiner, D. B. (1993a). Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 90, 4156-4160.
40. Wang, B., Boyer, J., Srikantan, V., Coney, L., Carrano, R., Phan, C., Merva, M., Dang, K., Agandjanan, M., Gilbert, L., Ugen, K. E., Williams, W. V., and Weiner, D. B. (1993b). DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell Bol. 12, 799-805.
41. Wei, X., Ghosh, S. K., Taylor, M. E., Johnson, V. A., Emini, E. A., Deutsch, P., Lifson, J. D., Bonhoeffer, S., Nowak, M. A., Hahn, B. H., Saag, M. S., and Shaw, G. M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 373, 117-122.
42. Yang, K., Mustafa, F., Valsamakis, A., Santoro, J. C., Griffin, D. E., and Robinson, H. L., (1996). Early studies on DNA-based immunizations for measles virus. Vaccine, in press.